File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it

TitleRhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it
Authors
Issue Date2010
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2010, v. 30 n. 5, p. 642-656 How to Cite?
AbstractHepatocellular carcinoma (HCC) is an intractable disease with an extremely high mortality rate. Metastasis is the major factor of liver failure, tumour recurrence and death in HCC patients. Unfortunately, no promising curative therapy for HCC metastasis is available as yet; therefore, treatment for advanced HCC still remains a formidable challenge. A large body of evidence has demonstrated that the RhoGTPases/Rho-effector pathway plays important roles in mediating HCC metastasis based on their foremost functions in orchestrating the cell cytoskeletal reorganization. This review will first discuss the general principles of cancer metastasis and cancer cell movement with a particular focus on HCC. We will then summarize the implications of various members in the RhoGTPases/Rho-effectors signalling cascade including the upstream RhoGTPase regulators RhoGTPases and Rho-effectors and their downstream targets in HCC metastasis. Finally, we will discuss the therapeutic insight of targeting the RhoGTPases/Rho-effector pathway in HCC. Taken together, the literature demonstrates the importance of the RhoGTPases/Rho-effector signalling pathway in HCC metastasis and marks the necessity to have a more thorough knowledge of this complicated signalling network in order to develop novel therapeutic strategies for HCC patients. © 2010 John Wiley & Sons A/S.
Persistent Identifierhttp://hdl.handle.net/10722/148625
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID
Funding AgencyGrant Number
Hong Kong Research Grants CouncilHKU 7/CRF/09
Funding Information:

The work was funded in part by Hong Kong Research Grants Council Collaborative Research Fund (HKU 7/CRF/09). I.O.L. Ng is Loke Yew Professor in Pathology.

References
Grants

 

DC FieldValueLanguage
dc.contributor.authorWong, CCLen_US
dc.contributor.authorWong, CMen_US
dc.contributor.authorAu, SLKen_US
dc.contributor.authorNg, IOLen_US
dc.date.accessioned2012-05-29T06:14:11Z-
dc.date.available2012-05-29T06:14:11Z-
dc.date.issued2010en_US
dc.identifier.citationLiver International, 2010, v. 30 n. 5, p. 642-656en_US
dc.identifier.issn1478-3223en_US
dc.identifier.urihttp://hdl.handle.net/10722/148625-
dc.description.abstractHepatocellular carcinoma (HCC) is an intractable disease with an extremely high mortality rate. Metastasis is the major factor of liver failure, tumour recurrence and death in HCC patients. Unfortunately, no promising curative therapy for HCC metastasis is available as yet; therefore, treatment for advanced HCC still remains a formidable challenge. A large body of evidence has demonstrated that the RhoGTPases/Rho-effector pathway plays important roles in mediating HCC metastasis based on their foremost functions in orchestrating the cell cytoskeletal reorganization. This review will first discuss the general principles of cancer metastasis and cancer cell movement with a particular focus on HCC. We will then summarize the implications of various members in the RhoGTPases/Rho-effectors signalling cascade including the upstream RhoGTPase regulators RhoGTPases and Rho-effectors and their downstream targets in HCC metastasis. Finally, we will discuss the therapeutic insight of targeting the RhoGTPases/Rho-effector pathway in HCC. Taken together, the literature demonstrates the importance of the RhoGTPases/Rho-effector signalling pathway in HCC metastasis and marks the necessity to have a more thorough knowledge of this complicated signalling network in order to develop novel therapeutic strategies for HCC patients. © 2010 John Wiley & Sons A/S.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1en_US
dc.relation.ispartofLiver Internationalen_US
dc.subject.meshCarcinoma, Hepatocellular - Enzymology - Pathologyen_US
dc.subject.meshCell Movementen_US
dc.subject.meshHumansen_US
dc.subject.meshLiver Neoplasms - Enzymology - Pathologyen_US
dc.subject.meshNeoplasm Metastasisen_US
dc.subject.meshRho Gtp-Binding Proteins - Metabolismen_US
dc.subject.meshRho-Associated Kinases - Metabolismen_US
dc.titleRhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move iten_US
dc.typeArticleen_US
dc.identifier.emailWong, CM:jackwong@pathology.hku.hken_US
dc.identifier.emailNg, IOL:iolng@hkucc.hku.hken_US
dc.identifier.authorityWong, CM=rp00231en_US
dc.identifier.authorityNg, IOL=rp00335en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1478-3231.2010.02232.xen_US
dc.identifier.pmid20726051-
dc.identifier.scopuseid_2-s2.0-77954373027en_US
dc.identifier.hkuros171420-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77954373027&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue5en_US
dc.identifier.spage642en_US
dc.identifier.epage656en_US
dc.identifier.isiWOS:000276502500003-
dc.publisher.placeUnited Statesen_US
dc.relation.projectMolecular Pathology of Liver Cancer - a Multidisciplinary Study-
dc.identifier.citeulike7016976-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats